INTRODUCTION Gastrointestinal acute graft-versus-host disease (GI aGVHD) remains a major clinical challenge in allogeneic haematopoietic stem cell transplantation (allo-HSCT) and is a leading cause of non-relapse mortality.1-4 Despite advances in donor selection and GVHD prophylaxis, approximately 40% of allo-HSCT recipients still develop GVHD, with GI involvement accounting for nearly 40% of cases.1-4 GI aGVHD often presents with severe complications, including bleeding, perforation and...